实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (2): 133-135.doi: 10.3969/j.issn.1672-5069.2014.02.006

• 肝衰竭 • 上一篇    下一篇

慢加急性乙型肝炎肝衰竭患者血浆脂联素水平的变化及其临床意义

王立志,孙文锦,汪燕,肖作汉   

  1. 436000 湖北省鄂州市中心医院感染病科
  • 收稿日期:2013-09-09 出版日期:2014-08-20 发布日期:2016-04-15
  • 通讯作者: 肖作汉 E-mail:41246751@qq.com
  • 作者简介:王立志,男,37岁,主治医师

Changes and clinical significance of plasma adiponectin in patients with hepatitis B virus-related acute-on chronic liver failure

Wang Lizhi,Sun Wenjin,Wang Yan,et al.   

  1. Department of Infectious Disease,Central Hospital of Ezhou,Ezhou 436000,Hubei Province,China
  • Received:2013-09-09 Online:2014-08-20 Published:2016-04-15

摘要: 目的 探讨慢加急性乙型肝炎肝衰竭(hepatitis B virus-related acute-on chronic liver failure,HBV-ACLF)患者血浆脂联素(adiponectin,ADPN)水平的变化及其临床意义。方法 纳入HBV-ACLF患者82例,采用酶联免疫法检测血浆脂联素水平;依据患者住院30d的预后情况将患者分为生存组和死亡组,计算终末期肝病模型(model for end-stage liver disease,MELD)评分;采用多因素Logistic回归分析,探讨血清ADPN水平和MELD评分评估HBV-ACLF 患者预后的价值。结果 24例早期、30例中期和28例晚期HBV-ACLF患者血浆ADPN水平分别为(0.68±0.15)ng/ml,(0.76±0.17) ng/ml和(0.89±0.18)ng/ml,随病程进展呈逐渐升高(F=12.30,P<0.01);30例生存患者性别、年龄、AST、ALT、白细胞、HBV DNA载量等与52例死亡患者无显著性差异,但生存患者血清ADPN和MELD评分分别为(0.7±0.2)ng/ml和(26.3±6.4),均显著低于死亡患者[(0.82±0.18)ng/ml和(37.9±8.1),P<0.01];多因素Logistic回归分析显示血浆ADPN水平(OR=1.23,95%CI:1.12~1.34,P<0.01)、MELD评分(OR=1.43,95%CI:1.22~1.65,P<0.01)、血清白蛋白 (OR=1.18,95%CI: 1.11~1.26,P<0.01)及AST/ALT比值(OR=1.06,95%CI:1.01~1.11,P<0.01)是影响HBV-ACLF患者近期预后的独立危险因素。结论 HBV-ACLF患者血浆ADPN水平与肝功能损害程度有关,其水平升高提示患者近期预后不良。

关键词: 肝功能衰竭, 乙型肝炎, 脂联素, 预后

Abstract: Objective To investigate the changes and clinical significance of plasma adiponectin(ADPN) in patients with hepatitis B virus-related acute-on chronic liver failure(HBV-ACLF). Methods Eighty-two patients with HBV-ACLF admitted to our department from Jan,2009 to Dec,2012 were included in this study. Clinical data were collected,and plasma ADPN was determined with ELISA. Patients were further divided into survival and dead group according to the clinical outcome at the end of 30 day hospitalization. The differences in plasma ADPN and model for end-stage liver disease (MELD) score between these two group were determined,and multivariate logistic regression analysis was used to evaluate the significance of ADPN and MELD score in prognosis of short-term survival. Results The plasma levels of ADPN at early-stage (n=24),middle-stage(n=30) and end-stage (n=28) of patients with HBV-ACLF were (0.68±0.15)ng/ml,(0.76±0.17) ng/ml and (0.89±0.18) ng/ml,respectively,which significantly increased with the progress of liver failure(F=12.30,P<0.01);No significant differences as respect to gender,age,AST,ALT,white blood cells and HBV DNA load were observed between 30 survival and 52 dead patients,however,the plasma ADPN and MELD scores in survival patients were (0.7±0.2)ng/ml and (26.3±6.4),respectively,both significantly lower than those in dead patients[(0.82±0.18)ng/ml and(37.9±8.1),respectively,P<0.01];Multivariate logistic regression analysis showed that MELD score(OR=1.43,95%CI:1.22-1.65,P<0.01),plasma level of ADPN (OR=1.23,95%CI:1.12-1.34,P<0.01),serum albumin (OR=1.18,95%CI:1.11-1.26,P<0.01) and AST/ALT ratio(OR=1.06,95%CI:1.01-1.11,P<0.01) were independent risk factors for short-term prognosis in patients with HBV-ACLF. Conclusions Plasma level of ADPN is associated with the progress of liver dysfunction,and an increase in plasma level of ADPN indicates a poor short-term prognosis in patients with HBV-ACLF.

Key words: Liver failure, Hepatitis B, Adiponectin, Prognosis